MICHELLE LYN: Open Payments
NPI 1265852339 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,889 in 41 payments from 8 companies in 2025. Trend: 2023 $537 · 2024 $666 · 2025 $1,889
Consulting: $950Food & beverage: $939
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 7 | $684 |
| Regeneron Pharmaceuticals, Inc. | 1 | $466 |
| Karyopharm Therapeutics Inc. | 16 | $215 |
| Janssen Biotech, Inc. | 6 | $169 |
| Legend Biotech USA Inc. | 2 | $143 |
| PFIZER INC. | 4 | $75 |
| Adaptive Biotechnologies Corporation | 3 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $62 |
Products named: LYNOZYFIC, CARVYKTI, XPOVIO, SARCLISA, ELREXFIO, clonoSEQ, TECVAYLI, NINLARO.
Industry payments across NY — which companies pay providers there.
